Bringing a new drug to market takes far longer than most people realise, even after regulators give the green light. In many cases, pharmaceutical companies still spend more than a year moving from approval to launch. The delay often comes from scattered data, slow manual work, and outdated tools that make it hard for teams to move fast. This is the gap an AI pharma platform like Cellbyte is trying to close.
The Munich-based startup has just raised $2.75 million in seed funding to speed up one of the most painful bottlenecks in the drug lifecycle. The round was led by Frontline Ventures with support from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels. The team believes that improving the launch phase can save companies time, money, and missed opportunities.
Cellbyte’s founders, Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, saw firsthand how much time pharmaceutical teams lose trying to find the right data at the right moment. Pricing documents sit in one folder, regulatory updates live somewhere else, and market access insights often arrive late. By the time everything is pulled together, the delay can stretch into months. They built Cellbyte to fix this by using AI to centralise information and automate the slowest parts of the workflow.
The company argues that a drug’s success is shaped long before it hits the market. Every launch depends on clean data, clear pricing structures, strong reimbursement strategies, and fast responses to regulators and partners. These tasks are complex on their own, but when handled across spreadsheets, emails, and legacy systems, they can overwhelm even the most experienced teams. Cellbyte’s AI pharma platform steps in to keep all of this in one place.
The system pulls data from clinical documents, pricing guidelines, HTA databases, and regulatory updates. It then uses natural language processing so teams can ask questions in simple language and get answers instantly. Instead of searching through PDFs or waiting for internal reports, they can ask the platform to compare countries, track market shifts, or highlight risks. The goal is simple: cut drug launch times by giving teams clarity without the manual drag.
Many pharma tech companies try to solve research or discovery, but Cellbyte focuses on the commercial end of the pipeline, where speed matters just as much. While platforms like Exscientia, CytoReason, or Confity focus on modelling or early insights, Cellbyte goes deeper into market access, pricing, and regulatory navigation. It acts as a live, always-updated dashboard for everything needed to get a drug ready for launch.
The platform also offers instant translations, which is a bigger deal than most people think. International teams often work with huge amounts of material in different languages, from German to Japanese. Translating these documents manually adds more time and cost. Cellbyte uses AI to break that barrier so teams can collaborate without slowing down.
The traction has been strong. Cellbyte already works with major brands such as Bayer and continues to grow across Europe and the U.S. The founders say that while drug discovery has embraced AI quickly, pricing and market access workflows have barely changed in the last decade. Now, with generative AI evolving fast, companies are finally ready to automate tasks they used to handle by hand.
The new funding will allow Cellbyte to expand its engineering team and scale operations as demand rises. The plan is to triple its headcount and build more advanced features that push the platform closer to its long-term goal: becoming the operating system for commercial pharma teams worldwide. That means bringing every pricing file, regulatory update, and market insight into one ecosystem powered by fast, reliable AI.
For the wider industry, a tool like Cellbyte signals a shift. Pharma companies have spent years accelerating research, improving trials, and investing in new science. Yet the final step, launching the drug, remains painfully slow. Teams know that each delay can limit patient access, weaken early revenue, and even reduce long-term market share. A modern AI pharma platform gives them a chance to move faster without sacrificing accuracy or compliance.
As the pressure grows for companies to bring treatments to patients sooner, platforms that centralise knowledge and reduce manual work will become essential. Cellbyte is betting that the future of pharmaceutical launches will rely on intelligence, automation, and a single place where all data comes together. With its new funding, the company now has the runway to push that vision further and reshape how the industry moves from approval to launch.
